Converge Bio Secures $2.5M Grant from Gates Foundation to Expand AI-Powered Gene Discovery Platform into Climate-Resilient Crop Development

On June 2, 2026, Converge Bio, a generative AI laboratory in the life sciences sector, received a $2.5 million grant from the Bill & Melinda Gates Foundation for a period of 37 months to expand its drug modeling platform into the field of crop genomics.

As climate variability intensifies, global food systems face mounting adaptive pressures. Given the complexity and limited understanding of crop genomes, traditional breeding methods require 12 to 15 years to develop new crop varieties, making it difficult to keep pace with climate change. Converge Bio’s AI-driven “Virtual Cell” project treats crop genomes as interconnected systems, enabling the simultaneous analysis of millions of base pairs to identify genetic variants associated with climate resilience, thereby shortening the breeding cycle.

This grant aims to help researchers and growers identify highly resilient genetic patterns earlier, reduce the number of breeding cycles required for new crop varieties, lower vulnerability to environmental impacts, and also reflects confidence in the transformative potential of the Converge Bio platform in the field of crop science.

Converge Bio develops an artificial intelligence platform to help biotechnology and pharmaceutical companies accelerate drug discovery and development. Founded in 2024, the company has 40 employees and a core team with strong professional backgrounds.

Disclaimer: The market involves risks, and investment should be approached with caution. This article was generated by an AI large language model based on publicly available information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making. For accurate information, please refer to the actual announcements. If you have any questions, please contact: biz@staff.sina.com.cn.

Responsible Editor: Xiaolang Express